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S204 Poster Session Ihave failed prior mobilization with G-CSF 6 chemotherapy. The
minimum and optimal cell dose for transplant was collected in
91% and 64% of the patients, respectively. Future studies should ex-
plore the safety and efficacy of P +G in front-line mobilization of
amyloidosis pts.
Table 1. Remobilization OutcomesNo. of Patients 11
Median age (range) 61 (48-73)
Gender, male (%) 10 (90.9)
Median CD341Cells/kg x 106 Collected
(range)
6.61 (1.63-17.67)No. of patients collecting $2 x 106 CD341
cells/kg (%)10 (90.9)No. of patients collecting $5 x 106 CD341
cells/kg (%)7 (63.6)No. of patients proceeding to transplant (%) 10 (90.9)
Median days to platelet engraftment (range) 19 (7-25)
Median days to neutrophil engraftment (range) 14 (6-27)124
G-CSF+/- PLERIXAFOR IS SUPERIOR TO CYCLOPHOSPHAMIDE + G/GM-
CSF FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLS (AHSC) MOBILIZA-
TION
Miller, A.N., Hogan, K.R., Alexander, E., Schaub, C., Fouts, T.,
Stuart, R.K., Costa, L.J. Medical University of South Carolina, Charles-
ton, SC
Background:The idealmethod tomobilize AHSC is unknown. The
use of chemotherapy (mostly cyclophosphamide) + growth factors,
when compared with the use of growth factors only, has the advan-
tage of higher HSC yield and fewer mobilization failures but is asso-
ciated with more complications. The use of the CXCR-4/SDF-1
binding inhibitor plerixafor, added to growth factor, may overcome
the limitations to the use of growth factor mobilization without che-
motherapy
Methods: We have developed a cost-saving decision making algo-
rithm that utilizes the CD34+ count in the peripheral blood on the
4th day of G-CSF administration (PB-CD34+) and the target
CD34+ count for the specific patient (T-CD34+) to decide between
starting collection on day 4 and continuing G-CSF administration
only (G approach) or adding Plerixafor the night before each apher-
esis session and starting apheresis on day 5 (G + P approach) (MUSC
algorithm, presented at 2010 tandemmeeting).We compared the ef-
ficacy of AHSCmobilization for patients with lymphoma ormultiple
myeloma utilizing theMUSC algorithm (MA cohort) with an histor-
ical series of patients undergoing mobilization with cyclophospha-
mide 2000 mg/m2 followed by G-CSF and/or GM-CSF (CY
cohort).
Results: Overall 28 individuals (9 on G and 19 on G + P) are in-
cluded in MA and 81 in CY. Patient’s characteristics are displayed
in table 1. The mobilization failure rate was 0% in MA vs. 22% in
CY (P5 0.01). Of the 18 patients who failed mobilization in CY,
10 completed collection in a subsequent mobilization attempt.
None of patients in MA and 4 patients in CY had infectious compli-
cations requiring hospitalization during mobilization. Patients com-
pleting collection in MA had in average 1.68 days of apheresis, vs.
1.73 in CY (P5 n.s.). The median yield of CD34+/kg was 6.4 
106 (range 3-15.8) in MA vs. 7.7  106 (range 2.8-72.6) in CY
(P5 0.07). For the 19 patients in MA and 60 in CY who received
a first autologous transplant, the median interval between beginning
of mobilization and transplant D0 was 13 days (range 11-63) and 42
days (range 12-157) respectively (P\0.01). There were no differ-
ences between MA and CY approaches in time for absolute neutro-
phil count. 500/mm2 (median 12 days for both MA and CY) or
platelet count. 20,000/mm2 without platelet transfusion (median
12 days for both MA and CY).Conclusion:TheMUSCmobilization algorithm is reliable and pro-
vides faster and safer mobilization than the use of cyclophosphamide
+ growth factor.
Table 1. Characteristics of the patients
MA- N5 28 CY- N5 81Diagnosis
Multiple Myeloma 23 (82%) 33 (41%)
Lymphoma 5 (18%) 48 (59%)
Age
#60 17 (61%) 49 (60%)
.60 11 (39%) 32 (40%)Gender
Male 10 (36%) 42 (52%)
Female 18 (64%) 39 (48%)
Prior radiation 10 (36%) 14 (17%)Prior lines of therapy- Lymphomas
#2 5 (100%) 40 (83%)
.2 0 (0%) 8 (17%)Prior lines of therapy- Myeloma
1 10 (43%) 13 (39%)
.1 13 (57%) 20 (61%)Prior lenalidomide 14 (61%) 7 (21%)125
PHASE I STUDY OF VORINOSTAT (SAHA) AFTER AUTOLOGOUS TRANS-
PLANT FOR PATIENTS WITH HIGH RISK LYMPHOMA
Hofmeister, C.C., Lozanski, G., Baiocchi, R.A., Hade, E.M.,
Benson, D.M., Blum, K., Porcu, P., Byrd, J.C., Devine, S.M. The Ohio
State University, Columbus, OH
Only the minority of patients with high risk or high intermediate
risk lymphoma will be cured with autologous transplant. SAHA has
shown activity in relapsed lymphoma and there is preclinical evi-
dence that HDACs may render lymphoma cells more susceptible
to host immune killing.
Methods:The primary objective was to assess safety and tolerabil-
ity of SAHA after BEAM-conditioned autologous transplant start-
ing day +60 for 21 consecutive days of a 28-day cycle for up to 11
cycles with 4 cohorts 100-400 mg of SAHA daily. Secondary ob-
jectives included preliminary clinical activity, NK and Treg recov-
ery, response to Prevnar vaccination at cycles 1/3/5, and quality of
life data (CES-D, BFI, and FACT-G). Patients were eligible with
DLBCL (induction failure, stage III/IV at relapse, age. 60, or el-
evated LDH at relapse), FL (transformed or 2+ prior regimens),
HL (primary refractory or PET positive after salvage), MCL, or
T-cell NHL.
Results: 10 lymphoma patients (median age 59 y.o, range 25-75)
have been treated thus far with FL (1), MCL (4), NS-HL (1),
PTCL (2), ALK-1 negative ALCL (1), and angioimmunoblastic
T-cell (1). Two pts had a PR after salvage chemotherapy pre-trans-
plant while the remaining 8 were in a CR. All patients were in a CR
post transplant and three patients (200 mg SAHA cohort) have suf-
fered progressive disease (1 after cycle 10, 1 after cycle 3, and 1 after
cycle 1). Drug-related adverse events consisted of two episodes of
grade 4 neutropenia (neither was dose-limiting), two patients suf-
fered grade 3 neutropenia, two with grade 3 rash/pruritus, and one
with grade 3 anorexia which was dose-limiting. The other DLT
was persistent grade 2 neutropenia thought to be clinically signifi-
cant. Preliminary analysis of peripheral blood flow cytometry
(n5 6) obtained at the beginning of odd numbered cycles showed
that patients with progressive disease had decreases over time in
the%of late activatedCD3 +HLA-DR+ andCD3 +CD86 +T-cells
with increased CD3 +CD16 + CD56dim NKT cells and
CD4 +CD25 + CD127- Tregs.
Conclusion:This ongoing phase I study of SAHA is accruing at the
300 mg SAHA dose level and has more neutropenia in the post auto-
graft population. Additional flow cytometry and quality of life data
Poster Session I S205will be presented and compared to a control autograft population.
Deacetylase inhibition post autograft may have both clinical efficacy
and immunomodulatory activity.126
BORTEZOMIB AND HIGH DOSE MELPHALAN FOLLOWED BY AUTOLO-
GOUS STEM CELL TRANSPLANTATION (B-HDM/SCT) FOR THE TREAT-
MENT OF AL AMYLOIDOSIS: RESULTS OF A FEASIBILITY STUDY
Sanchorawala, V., Yanarella, L., Quillen, K., Sloan, J.M., Andrea, N.T.,
Finn, K.T., Seldin, D.C. Boston University Medical Center, Boston, MA
Aggressive treatment of AL amyloidosis with high dose melphalan
and autologous stem cell transplant (HDM/SCT) is effective in in-
ducing hematologic remission and clinical improvement. We have
observed in  500 patients treated with HDM/SCT that achieve-
ment of a hematologic complete response (CR) is a critical determi-
nant of clinical improvement and survival. A synergistic effect
between bortezomib (B) andmelphalan has been demonstrated in vi-
tro and in vivo. Thus, the combination of B and HDM is a logical
approach to study. Because of the importance of hematologic CR
in treatment outcome, we conducted a feasibility study to determine
whether addition of B to HDM/SCT would be tolerable and would
increase hematologic CR rates. Eligibility for entry into the trial re-
quired diagnosis of AL amyloidosis, age. 18 years, and adequate
performance status (SWOG# 2) and cardiopulmonary function
(LVEF. 45%, DLCO. 50%). Peripheral blood stem cells were
collected following G-CSF mobilization, with minimum yields of
2.5  106 CD34+ cells/kg required for participation in the trial. B
was administered at 1 mg/m2 on D -6, D -3, D +1, and D +4 and
HDM at 140-200 mg/m2 in two divided doses on D -2 and D -1.
From 10/2008 to 10/2009, 9 patients were enrolled (median age
53, range 46-68; median number of involved organs 2, range 1-4).
Of the 9 patients enrolled, 1 patient was removed from the protocol
because of cardiac arrhythmia during stem cell mobilization and col-
lection phase that precluded treatment with HDM/SCT. Of the 8
patients who received B-HDM/SCT, there was no treatment-related
mortality within 100 days of SCT and there were no unexpected he-
matologic or non-hematologic toxicities associated with addition of
B to HDM/SCT. The median times to neutrophil and platelet en-
graftment was D +10 and D +14 after SCT, respectively. Of 8 pa-
tients evaluable for early responses, normalization of serum free
light chain levels and ratio occurred in 7 of 8 (88%) by D +14 and
one patient achieved a 45% reduction in serum free light chain con-
centration at D +14. Of the initial 2 patients with longer follow-up,
both have achieved a hematologic CR at 6 and 9months following B-
HDM/SCT. Follow-up is ongoing and hematologic responses ap-
pear to be well-maintained. Thus, this pilot study demonstrates
that B-HDM/SCT is tolerable for selected patients with AL amy-
loidosis and leads to a high rate of hematologic responses.127
TRANSPLANT ASSOCIATED-THROMBOTIC MICROANGIOPATHY (TA-
TMA) IN PEDIATRIC NEUROBLASTOMA (NB) PATIENTS UNDERGOING
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): A CASE-CONTROL
STUDY IDENTIFYING EARLY CLINICAL MARKERS OF DISEASE
Laskin, B.L.1, Goebel, J.1, Davies, S.M.2, Bleesing, J.J.2, Mehta, P.A.2,
Filipovich, A.H.2, Khoury, J.C.3, Paff, Z.N.2, Jodele, S.2 1Cincinnati
Children’s Hospital Medical Center (CCHMC), OH; 2Cincinnati Child-
ren’s Hospital Medical Center, OH; 3Cincinnati Children’s Hospital Med-
ical Center, OH
Patients (pts) undergoing ASCT for NB present a unique popula-
tion to studyTA-TMAdue to their standardized chemotherapy, lack
of graft-versus host disease prophylaxis, and subsequent exposure to
radiation and cis-retinoic acid (cisRA).We performed a retrospective
case-control study of TA-TMA in NB pts who underwent ASCT at
CCHMC in the past 5 years to identify strategies for early rigorous
diagnosis. Twenty pts with high risk NB were treated with melpha-
lan, carboplatin, and etoposide followed by ASCT. Six pts were di-
agnosed with TA-TMA (4 within 25 days of ASCT) presenting
with microangiopathic hemolytic anemia, elevated lactate dehydro-genase, thrombocytopenia, hypertension (HTN), and acute kidney
injury (3 confirmedwith renal biopsy). Adenovirus, cytomegalovirus,
and influenza B were potential triggers of TA-TMA (n5 2). The 14
pts without TA-TMA served as controls. Clinical and laboratory
data were obtained for the first 30 days pre- and post-ASCT. Blood
pressure (BP) index was calculated as BP/95th percentiles for age and
height (value .15HTN). No pt had HTN pre-ASCT. Fischer’s
exact test, Wilcoxon rank sum and generalized linear models were
used for analysis. Results are shown in the Table. Proteinuria, hema-
turia, and schistocytes on blood smear were significantly associated
with TA-TMA, while blood and platelet transfusions were not.
HTN requiring therapy proved to be a very significant indicator of
TA-TMA and was identified within days of ASCT. Although serum
creatinine (SCr) did not differ significantly between groups, pts with
TA-TMA had an average 60% decrease in renal function from base-
line by nuclear glomerular filtration rate (nucGFR) post ASCT,
compared to a 30% decrease in those without TA-TMA. TA-
TMA therapy included steroids, plasmapheresis, and rituximab.
There was no TA-TMA-related mortality, but significant complica-
tions included progression to chronic dialysis (n5 1) and severe pol-
yserositis (n5 2). None of the pts with TA-TMA were able to
complete cisRA therapy. Overall, we found a 30% prevalence of
TA-TMA in transplanted NB pts. The most significant indicator
of TA-TMA was HTN. Our data are limited by their retrospective
nature and small sample size.We suggest that careful BP observation
and urinalysis monitoring will assist in the early diagnosis of TA-
TMA, while SCr measurements are of limited value. Prospective
studies are needed to confirm these results as early diagnosis and
treatment may eventually help to improve outcome.
Indicators of TA-TMA during first month post-ASCT
TA-TMA No TA-TMA
Variable (n5 6) (n5 14) P-valueProteinuria 4 (67%) 2 (15%) 0.046
Hematuria 4 (67%) 1 (8%) 0.02
Schistocytes 4 (67%) 1 (8%) 0.02
Pre-ASCT NucGFR 152.06 12.9 145.66 10.9 0.64
Post-ASCT NucGFR* 61.06 8.8 103.16 6.2 0.002
SCr (mg/dL) 0.546 0.04 0.496 0.02 0.28
Systolic BP (mm Hg) 112.26 2.5 102.26 1.6 0.004
Diastolic BP (mm Hg) 66.76 2.2 55.46 1.5 0.001
Systolic Index 1.026 0.02 0.926 0.02 0.002
Diastolic Index 0.996 0.04 0.816 0.02 0.001
Pts requiring HTN therapy 5 (83%) 3 (21%) 0.006Data n (%) or mean6 standard error. *NucGFR (ml/min/1.73 m2) done
on average 61 days post-ASCT128
IS LOW DOSE CYCLOPHOSPHAMIDE PLUS G-CSF MOBLIZATION AS EF-
FECTIVE AS MOZOBIL (PLERIXAFOR) PLUS G-CSF IN MULTIPLE MYE-
LOMA (MM) PATIENTS ELIGIBLE FOR TANDEM TRANSPLANT?
Karanes, C.1, Dagis, A.3, Wang, S.4, Krishnan, A.1, Sahebi, F.1,
Popplewell, L.1, Parker, P.1, Forman, S.1, Palmer, J.3, Kogut, N.1,
Somlo, G.2 1City of Hope, Duarte, CA; 2City of Hope, Duarte, CA;
3City of Hope, Duarte, CA; 4City of Hope, Duarte, CA
Introduction: A recent study showed 71.6% of patients who re-
ceived plerixafor plus G-CSF collected .6  106 CD34+ cells/kg
in# 2 apheresis procedures when compared to placebo plus G-
CSF.We analyzed retrospectively two tandem autologous transplant
protocols where cyclophosphamide plus G-CSF (Cy-G) was used as
mobilization therapy.
Methods: From 08/1999 to 06/2009, 120 MM patients were en-
rolled. Patients received 1.5 g/m2 of Cy followed byG-CSF. Patients
underwent consecutive leukapheresis starting on day 10 and contin-
ued until a minimum of 4x 106 CD34+/kg was collected and 6 106
CD34+/kg when possible.
Results:Median days to reach 4x 106 CD34+/kg was 1 (1-16) and for
6 106 CD34+/kg was 2 (1-16). Median days of total apheresis was 3
